| Budget Amount *help |
¥127,920,000 (Direct Cost: ¥98,400,000、Indirect Cost: ¥29,520,000)
Fiscal Year 2015: ¥23,140,000 (Direct Cost: ¥17,800,000、Indirect Cost: ¥5,340,000)
Fiscal Year 2014: ¥23,140,000 (Direct Cost: ¥17,800,000、Indirect Cost: ¥5,340,000)
Fiscal Year 2013: ¥24,440,000 (Direct Cost: ¥18,800,000、Indirect Cost: ¥5,640,000)
Fiscal Year 2012: ¥24,180,000 (Direct Cost: ¥18,600,000、Indirect Cost: ¥5,580,000)
Fiscal Year 2011: ¥33,020,000 (Direct Cost: ¥25,400,000、Indirect Cost: ¥7,620,000)
|
|---|
| Outline of Final Research Achievements |
We provided the first successful demonstration of in-vivo PET imaging of tau protein lesions in diverse neurological disorders. A new, widely available SPECT tracer for amyloid-beta peptide aggregates was also developed and applied to animal models. Novel radioprobes for translocator protein (TSPO), a biomarker for neuroinflammation, enabled high-contrast PET imaging, and essential roles of TSPO in neurosteroid production were revealed using knockout and transgenic models. Progresses in neurotransmission PET imaging in this project include development of imaging agents for metabotropic glutamate receptors, AMPA receptors and histamine H3 receptors. We also enabled reporter imaging in the brains of living rodents and monkeys by visualizing Designer Receptors Exclusively Activated by Designer Drugs (DREADD), along with chemogenetic controls of neuronal activities via DREADD systems.
|
